(Q37766798)

22 August 2017

1 reference

title

Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives (English)

1 reference

22 August 2017

main subject

hepatocellular carcinoma

1 reference

Ying-Chun Shen

1

1 reference

22 August 2017

Chiun Hsu

series ordinal

2

1 reference

22 August 2017

Ann-Lii Cheng

series ordinal

3

1 reference

22 August 2017

publication date

22 June 2010

1 reference

Journal of Gastroenterology

22 August 2017

published in

1 reference

22 August 2017

volume

45

1 reference

22 August 2017

issue

8

1 reference

22 August 2017

page(s)

794-807

1 reference

Efficacy and safety of thalidomide in patients with hepatocellular carcinoma

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0270-0

Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: complete regression of hepatoma growth and metastasis by dual mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0270-0

PTEN / MMAC1 mutation and frequent loss of heterozygosity identified in chromosome 10q in a subset of hepatocellular carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0270-0

Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0270-0

Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0270-0

Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma

21 January 2018

1 reference

12 December 2020

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301

1 reference

12 December 2020

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

1 reference

12 December 2020

Expression of hepatocyte growth factor (HGF) and HGF receptor (c-met) proteins in liver diseases: an immunohistochemical study

1 reference

12 December 2020

Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009.

1 reference

12 December 2020

Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma.

1 reference

12 December 2020

A study on angiogenesis-related matrix metalloproteinase networks in primary hepatocellular carcinoma

1 reference

12 December 2020

The IGF axis and hepatocarcinogenesis

1 reference

12 December 2020

Current strategy for staging and treatment: the BCLC update and future prospects.

1 reference

12 December 2020

Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.

1 reference

12 December 2020

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

1 reference

12 December 2020

Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma

1 reference

12 December 2020

High expression of insulin-like growth factor binding protein-3 is correlated with lower portal invasion and better prognosis in human hepatocellular carcinoma

1 reference

12 December 2020

Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design

1 reference

12 December 2020

Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

1 reference

12 December 2020

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

1 reference

12 December 2020

Dysregulation of growth factor signaling in human hepatocellular carcinoma.

1 reference

12 December 2020

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

1 reference

12 December 2020

alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma

1 reference

12 December 2020

Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib

1 reference

12 December 2020

Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells.

1 reference

12 December 2020

Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets

1 reference

12 December 2020

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo

1 reference

12 December 2020

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

1 reference

12 December 2020

Molecular basis for sunitinib efficacy and future clinical development

1 reference

12 December 2020

Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma

1 reference

12 December 2020

Biomarkers of response and resistance to antiangiogenic therapy

1 reference

12 December 2020

DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents

1 reference

12 December 2020

Molecular and cellular biomarkers for angiogenesis in clinical oncology

1 reference

12 December 2020

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.

1 reference

12 December 2020

Pivotal role of mTOR signaling in hepatocellular carcinoma

1 reference

12 December 2020

Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis

1 reference

12 December 2020

Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours

1 reference

12 December 2020

A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas

1 reference

12 December 2020

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme

1 reference

12 December 2020

The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.

1 reference

12 December 2020

HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion

1 reference

12 December 2020

The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma

1 reference

12 December 2020

Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma

1 reference

12 December 2020

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

1 reference

12 December 2020

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

1 reference

12 December 2020

FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer

1 reference

12 December 2020

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer

1 reference

12 December 2020

Liver disease selectively modulates cytochrome P450--mediated metabolism

1 reference

12 December 2020

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma

1 reference

12 December 2020

Cancer biomarkers--an invitation to the table

1 reference

12 December 2020

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

12 December 2020

Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development

1 reference

12 December 2020

Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis

1 reference

12 December 2020

Thalidomide is an inhibitor of angiogenesis

1 reference

12 December 2020

The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes.

1 reference

12 December 2020

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

1 reference

12 December 2020

Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling.

1 reference

12 December 2020

Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor

1 reference

12 December 2020

Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome

1 reference

12 December 2020

Sorafenib in advanced hepatocellular carcinoma

1 reference

12 December 2020

Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer.

1 reference

12 December 2020

A quantitative analysis of kinase inhibitor selectivity

1 reference

12 December 2020

The TOR pathway: a target for cancer therapy

1 reference

12 December 2020

Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines.

1 reference

12 December 2020

Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

1 reference

12 December 2020

Impact of biospecimens handling on biomarker research in breast cancer

1 reference

12 December 2020

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

1 reference

12 December 2020

Modes of resistance to anti-angiogenic therapy

1 reference

12 December 2020

HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy.

1 reference

12 December 2020

Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression

1 reference

12 December 2020

Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.

1 reference

12 December 2020

Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy

1 reference

12 December 2020

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

1 reference

12 December 2020

Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor

1 reference

12 December 2020

Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma.

1 reference

12 December 2020

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

12 December 2020

Growth factors as therapeutic targets in HCC.

1 reference

12 December 2020

Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma

1 reference

12 December 2020

Impact of sample acquisition and linear amplification on gene expression profiling of lung adenocarcinoma: laser capture micro-dissection cell-sampling versus bulk tissue-sampling

1 reference

12 December 2020

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

1 reference

12 December 2020

Serum endostatin predicts tumor vascularity in hepatocellular carcinoma

1 reference

12 December 2020

Targeting HIF-1 for cancer therapy

1 reference

12 December 2020

Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib

1 reference

12 December 2020

Hepatitis C virus core protein induces cell proliferation and activates ERK, JNK, and p38 MAP kinases together with the MAP kinase phosphatase MKP-1 in a HepG2 Tet-Off cell line

1 reference

12 December 2020

Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples

1 reference

12 December 2020

Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma

1 reference

12 December 2020

Thalidomid: current role in the treatment of non-plasma cell malignancies.

1 reference

12 December 2020

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

12 December 2020

Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis

1 reference

12 December 2020

Membrane-type matrix metalloproteinase-1(MT1-MTP) gene is overexpressed in highly invasive hepatocellular carcinomas

1 reference

12 December 2020

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?

1 reference

12 December 2020

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

1 reference

12 December 2020

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma

1 reference

12 December 2020

Metronomic scheduling: the future of chemotherapy?

1 reference

12 December 2020

Parallel hybridization analysis of multiple protein kinase genes: identification of gene expression patterns characteristic of human hepatocellular carcinoma

1 reference

12 December 2020

Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma.

1 reference

12 December 2020

IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

1 reference

12 December 2020

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

12 December 2020

Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma.

1 reference

12 December 2020

Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma

1 reference

12 December 2020

Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma

1 reference

12 December 2020

Epidermal growth factor receptor in human hepatocellular carcinoma

1 reference

12 December 2020

Influence of slide aging on results of translational research studies using immunohistochemistry

1 reference

12 December 2020

Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells

1 reference

12 December 2020

Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma

1 reference

12 December 2020

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

1 reference

12 December 2020

FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer

1 reference

12 December 2020

Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential

1 reference

12 December 2020

Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma

1 reference

12 December 2020

Opportunities for targeted therapies in hepatocellular carcinoma

1 reference

12 December 2020

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

12 December 2020

Gene expression in Barrett's esophagus: laser capture versus whole tissue

1 reference

12 December 2020

Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells

1 reference

12 December 2020

Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

1 reference

12 December 2020

HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity

1 reference

12 December 2020

Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells

1 reference

12 December 2020

Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway

1 reference

12 December 2020

Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning

1 reference

12 December 2020

1 reference

12 December 2020

Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma

1 reference

12 December 2020

Molecular classification and novel targets in hepatocellular carcinoma: recent advancements

1 reference

12 December 2020

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

mTOR and P70 S6 kinase expression in primary liver neoplasms

1 reference

12 December 2020

Low-dose thalidomide treatment for advanced hepatocellular carcinoma

1 reference

12 December 2020

Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology

1 reference

12 December 2020

The anti-angiogenic basis of metronomic chemotherapy

1 reference

12 December 2020

Distinct chromosomal bias of gene expression signatures in the progression of hepatocellular carcinoma.

1 reference

12 December 2020

Gene expression patterns in human liver cancers

1 reference

12 December 2020

Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection.

1 reference

12 December 2020

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

1 reference

12 December 2020

Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer

1 reference

12 December 2020

Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma

1 reference

12 December 2020

Angiogenesis inhibitors: motivators of metastasis?

1 reference

12 December 2020

Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

1 reference

12 December 2020

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

1 reference

12 December 2020

Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial

1 reference

12 December 2020

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival

1 reference

12 December 2020

A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.

1 reference

12 December 2020

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

1 reference

12 December 2020

10.1007/S00535-010-0270-0

Identifiers

DOI

1 reference

22 August 2017

1 reference